IDEXX Laboratories Shares Return to Historical Valuation after 39.3% Annual Rally
Conestoga Capital Advisors highlighted IDEXX Laboratories in its Q4 2025 letter after consistent earnings beats and resilient organic revenue growth drove shares back to historical average valuation. Shares closed at $630.73 on Feb. 19, 2026, down 9.10% one month and up 39.30% twelve months, with a $50.461 billion market cap.
1. Conestoga Capital Letter
In its Q4 2025 investor letter, Conestoga Capital Advisors noted IDEXX Laboratories as a top selection, praising the company’s consistent earnings beats and resilient organic revenue growth that have driven its share valuation back to historical averages.
2. Recent Stock Performance
IDEXX Laboratories shares closed at $630.73 on February 19, 2026, reflecting a 9.10% decline over the previous month and a 39.30% gain over the past twelve months, corresponding to a $50.461 billion market capitalization.
3. Hedge Fund Ownership Trends
Hedge fund holdings of IDEXX Laboratories rose from 48 to 55 portfolios in the third quarter, indicating growing institutional interest in the diagnostics and veterinary healthcare specialist.